SCHEMBL6600972

SCHEMBL6600972

COc1ccc(C2=NN(C(=O)c3ccccc3NC(=O)c3cccnc3)CCC2)cc1OC1CCCC1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 4/20 0.53
PDE4D Q08499 8/20 0.48
PDE4A P27815 6/20 0.48
PDE4B Q07343 5/20 0.48
PDE4C Q08493 5/20 0.48
ALDH1A1 P00352 1/20 0.47
AAK1 Q2M2I8 2/20 0.45
MAPT P10636 1/20 0.45
PDE1A P54750 1/20 0.45
PDE1B Q01064 1/20 0.45
PDE1C Q14123 1/20 0.45
KDM4E B2RXH2 1/20 0.44
POLB P06746 1/20 0.43
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143512 0.92 AAK1 (0.52) PDE4BALDH1A1AAK1MAPTKDM4E
SCHEMBL6603362 0.92 PDE5A (0.54) PDE5APDE4DPDE4APDE4BPDE4C
SCHEMBL145065 0.88 PDE4A (0.51) PDE5APDE4DPDE4APDE4BPDE4C
SCHEMBL6602823 0.88 AAK1 (0.48) PDE4BALDH1A1AAK1MAPTKDM4E
Hydrochloric Acid SCHEMBL7646226 0.87 PDE4D (0.50) PDE5APDE4DPDE4APDE4BPDE4C
SCHEMBL145758 0.87 PDE5A (0.49) PDE5APDE4DPDE4APDE4BPDE4C
SCHEMBL8208033 0.86 SMN1; SMN2 (0.50) PDE5APDE4DPDE4APDE4BPDE4C
SCHEMBL6601582 0.83 MAOB (0.48) PDE4BALDH1A1AAK1MAPTPOLB
SCHEMBL6601874 0.83 ABCG2 (0.47) PDE5APDE4DPDE4APDE4BPDE4C
SCHEMBL27557634 0.82 MKNK1 (0.45) PDE4DPDE4APDE4BPDE4CALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0922036-B1 ARYLALKANOYL PYRIDAZINES MERCK PATENT GMBH (DE) 2004-03-24 EP disclosed
US-6479494-B1 THEY INHIBIT SELECTIVELY PHOSPHODIESTERASE IV, WHICH CAUSES AN INCREASE OF THE INTRACELLULAR CAMP LEVEL AS CAMP INHIBITS BONE DECREASING CELLS AND STIMULATES BONE INCREASING CELLS FOR TREATMENT OF OSTEOPOROSIS MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2002-11-12 US disclosed
EP-0922036-A1 ARYLALKANOYL PYRIDAZINES MERCK PATENT GmbH (DE) 1999-06-16 EP disclosed
WO-1998006704-A1 ARYLALKANOYL PYRIDAZINES MERCK PATENT GMBH (DE) 1998-02-19 WO disclosed